REVIEW

Recent advances in understanding West Nile virus host immunity and viral pathogenesis [version 1; peer review: 2 approved]

Huanle Luo¹, Tian Wang ¹⁻³

¹Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, USA

²Department of Pathology, University of Texas Medical Branch, Galveston, USA

³Institute for Human Infections & Immunity, University of Texas Medical Branch, Galveston, USA

V1 First published: 19 Mar 2018, 7(F1000 Faculty Rev):338
<https://doi.org/10.12688/f1000research.13362.1>

Latest published: 19 Mar 2018, 7(F1000 Faculty Rev):338
<https://doi.org/10.12688/f1000research.13362.1>

Abstract

West Nile virus (WNV), a mosquito-borne flavivirus, has been a significant public health concern in the United States for nearly two decades. The virus has been linked to acute viral encephalitis, neurological sequelae, and chronic kidney diseases. Neither antiviral drugs nor vaccines are currently available for humans. *In vitro* cell culture and experimental animal models have been used to study WNV infection in humans. In this review, we will focus on recent findings and provide new insights into WNV host immunity and viral pathogenesis.

Keywords

West Nile Virus, Pathogenesis, Animal models, Host Immunity

Open Peer Review

Approval Status

	1	2
version 1		
19 Mar 2018		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Aaron C Brault**, Centers for Disease Control and Prevention, Fort Collins, USA
2. **Helle Bielefeldt-Ohmann**, Australian Infectious Diseases Research Centre, The University of Queensland, Queensland, Australia

Any comments on the article can be found at the end of the article.

Corresponding author: Tian Wang (ti1wang@utmb.edu)

Author roles: Luo H: Writing – Original Draft Preparation, Writing – Review & Editing; Wang T: Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported in part by National Institutes of Health grant R01AI099123 (T.W.) and R01AI127744 (T.W.). *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2018 Luo H and Wang T. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Luo H and Wang T. **Recent advances in understanding West Nile virus host immunity and viral pathogenesis [version 1; peer review: 2 approved]** F1000Research 2018, 7(F1000 Faculty Rev):338 <https://doi.org/10.12688/f1000research.13362.1>

First published: 19 Mar 2018, 7(F1000 Faculty Rev):338 <https://doi.org/10.12688/f1000research.13362.1>

Introduction

West Nile virus (WNV), a mosquito-borne, single-stranded, positive-sense flavivirus, has been a significant public health concern in the United States for nearly two decades. It was originally isolated in Uganda in 1937 and later caused epidemics in Africa, Europe, the Middle East, and parts of Asia. The virus was introduced to the United States in 1999, and since then it has caused more than 46,000 confirmed human cases and about 2,000 deaths^{1,2}. While the majority of human infections are asymptomatic, about 20% of infected individuals become symptomatic and develop flu-like symptoms such as rash, headache, myalgia, and gastrointestinal discomfort. Less than 1% of all infected people develop severe neurological disease, including encephalitis, meningitis, acute flaccid paralysis, and death. Up to 50% of WNV convalescent patients develop persistent neurological sequelae or chronic kidney diseases³⁻⁵. Currently, neither treatments nor approved vaccines are available for use in humans to protect against WNV infection. Both *in vitro* cell culture and experimental animal models have been used to study WNV infection in humans. In this review, we will mainly focus on the findings made within the last five years and provide new insights into WNV host immunity and viral pathogenesis.

Host immunity

Innate immunity

WNV activates the signaling pathways of several pathogen recognition receptors (PRRs), including Toll-like receptors (TLRs) 3 and 7, RIG-I-like receptors (RLRs), and NOD-like receptors containing pyrin domain (NLRPs), in order to boost innate immunity and culminate in the synthesis of antiviral cytokines, including type I interferons (IFNs), proinflammatory cytokines and chemokines⁶⁻⁹. The cytosolic DNA sensor cyclic GMP–AMP synthase (cGAS) is also pivotal in protecting the host from WNV infection, though the underlying mechanism has not been defined¹⁰. TLR8, the natural ligand for which remains unknown, associates with suppressor of cytokine signaling 1 (SOCS-1) and inhibits the TLR7-mediated antiviral immune response to facilitate WNV infection in mice¹¹.

IFN responses contribute to host defense mainly in two ways. First, IFNs and IFN-stimulating genes (ISGs), including *Ifit2*, *Ifi2712a*, and *Ifitm3*, participate in the control of WNV infection, prevent the virus from invading the central nervous system (CNS), and restrict its spread in the brain¹²⁻¹⁶. Second, both type I and type III IFNs (IFN- λ) are implicated in promoting blood–brain barrier (BBB) integrity, which may prevent WNV entry to the CNS. Studies in murine models suggest that type I IFNs are directly involved in the permeability of the endothelium and the formation of tight junctions through balanced activation of Rac1 and RhoA—small guanosine triphosphatases (GTPases)—interactions and indirect suppression of the compromise effects of proinflammatory cytokines¹⁷. More recently, Daniels *et al.* reported that type I IFNR signaling in astrocytes regulates BBB permeability and protects the cerebellum from WNV infection and immunopathology¹⁸. Furthermore, the activation of TAM receptor Mertk synergizes with IFN- β to tighten cell junctions and prevent WNV transit across brain

microvascular endothelial (BMVE) cells. As a consequence, mice deficient of Mertk were highly vulnerable to a neuroinvasive WNV strain infection¹⁹. IFN- λ signaling also modulates tight junction protein localization in a signal transducer and activator of transcription 1 (STAT1)-independent manner in mouse BMVE cells, which leads to a rise in transendothelial electrical resistance and a fall in the movement of virus across the BBB during WNV infection²⁰. Multiple host and viral factors have been reported to be involved in regulating IFN signaling during WNV infection. For example, IRF-3, -5, and -7 are the key transcription factors responsible for mediating type I IFN and ISG responses downstream of RLR signaling in WNV-infected myeloid dendritic cells (DCs)²¹. Another transcription factor, ELF4, is recruited by STING following WNV infection and interacts with the mitochondrial antiviral-signaling protein (MAVS)–TBK1 complex, which is critical for further induction of type I IFN responses²². Both PI3K/Akt and microRNA miR-34a inhibit WNV infection by positively regulating type I IFN signaling^{23,24}. Several factors also contribute to the negative regulation of IFN responses. Among them, the activating signal cointegrator complex 3 (ASCC3) protein functions to suppress ISG expression in an IRF3- and IRF7-dependent manner²⁵. UBXN1, a UBX-domain-containing protein family member, can bind to MAVS, the central adaptor protein to RLR signaling, and disrupt IFN-mediated antiviral immune responses²⁶. The nonstructural protein NS1 of WNV is secreted upon infection and associates with and represses TLR3-induced IFN responses in both human and mouse cells²⁷. Among the proinflammatory cytokines induced during WNV infection, interleukin (IL)-1 β was shown to synergize with type I IFN and suppress WNV replication in mouse cortical neurons⁹. Systems immunology studies in cohorts of human subjects with a history of WNV infection also reveal IL-1 β induction as a predictive signature of susceptibility to WNV infection²⁸. Several chemokines and their receptors have been demonstrated to play an important role in facilitating immune cell infiltration to the CNS for WNV clearance. The CCR2 chemokine ligands CCL2 and CCL7 are both involved in monocytoysis and monocyte accumulation in the brain. However, CCL7 seems to play a larger role in WNV-induced monocytoysis and is involved in the efficient recruitment of neutrophils and CD8⁺ T cells into the CNS²⁹. CCR5 is required for virologic control, specifically within the CNS cortex. WNV-infected CCR5^{-/-} mice had a significant decrease in immune cell infiltrates, increased BBB permeability, and elevated levels of CCR5 ligands³⁰. Several factors are important for promoting chemokine-mediated leukocyte migration. For example, CD22 is essential in the control of WNV infection. It was expressed on a subset of splenic DCIR2⁺ DCs in mice, which rapidly expanded early after WNV infection, produced CCL3, and promoted CD8⁺ T cell migration into the CNS³¹. Another study reported that receptor-interacting protein kinase 3 (RIPK3) promotes the production of the chemokines CCL2 and CXCL10 in neurons following WNV infection in mice and this helps to recruit T lymphocytes and inflammatory myeloid cells to the CNS for viral clearance³². Finally, studies in horses infected with a newly emerging WNV strain, WNV_{NSW2011}³, suggest that early IFN and inflammatory cytokine responses in circulating leukocytes and lymphoid organs are associated with subclinical WNV infection³³.

PRR-mediated signaling pathways are also involved in regulating the effector activities of innate immune cells. $\gamma\delta$ T cells are important for the early control of WNV dissemination and regulation of adaptive immunity against WNV infection. Following WNV infection, TLR7 provides co-stimulatory signals during TCR activation of $\gamma\delta$ T cells³⁴. Furthermore, the dysregulated TLR7 signaling pathways due to aging lead to impaired $\gamma\delta$ T cell expansion in old mice vaccinated with an attenuated WNV mutant strain³⁵. The RLR and IFN signaling pathways contribute to the regulation of natural killer cell effector activities and the control of pathological inflammation induced in myeloid cells, respectively³⁶. MAVS expression on hematopoietic cells is critical for regulating the inflammatory response and protecting the host from lethal WNV infection³⁷.

Adaptive immunity

Mature B cells and WNV-specific antibodies are critical in the control of WNV infection and dissemination. However, a recent study suggests that immature B cells present in B-cell-activating factor receptor-deficient mice also contribute to antiviral immunity and protect the host in passive and active immunizations³⁸. T cells provide long-lasting protection against WNV. Graham *et al.* demonstrated in WNV-infected mice that the regulatory T cell (Treg)-dependent production of transforming growth factor beta is required for the induction of CD103 expression on CD8⁺ T cells, thereby generating and maintaining a large pool of WNV-specific resident memory CD8⁺ T cells³⁹. Aging is a known risk factor for WNV-induced encephalitis in mice and humans. Old mice display an enhanced vulnerability to WNV infection, partially due to cell-trafficking defects in the draining lymph nodes, which result in delayed T cell recruitment and antigen recognition and an impaired IgM and IgG response⁴⁰.

PRR-mediated innate immunity plays an important role in regulating T- and B-cell responses during WNV infection. For example, both TLR3- and MyD88-dependent signaling pathways contribute to the development of WNV-specific antibody and B-cell memory responses following immunization with a single-cycle WNV vaccine⁴¹. MAVS and TLR7 are both required for T-cell priming but are dispensable for recall T-cell responses following an attenuated WNV strain infection. Instead, the TLR7-independent MyD88 signaling pathways, such as IL-1 receptor (IL-1R) signaling, are involved in memory T-cell development^{42,43}. Both IL-1R and RLR-mediated innate signaling pathways are required for optimal CD4⁺ and CD8⁺ T-cell activation and subsequent clearance of WNV in the CNS^{44–46}. Other innate factors, such as IL-17A, are required for promoting CD8⁺ T-cell cytotoxicity and WNV clearance⁴⁷. Lastly, although the intrinsic MAVS signaling is dispensable for Treg proliferation and suppressive capacity, the overproduction of proinflammatory cytokines generated in MAVS-deficient mice contributes to a failure of Treg expansion⁴⁸.

WNV pathogenesis

WNV entry into the CNS and induction of encephalitis

Following natural transmission to the host via mosquito bites, WNV replicates in keratinocytes and the skin residential DCs, Langerhans cells (LCs). Activated LCs then migrate to local

draining lymph nodes from the epidermis, after which viremia begins and WNV disseminates to the kidneys, spleen, and other visceral organs⁴⁹. Although how WNV enters the CNS is not clearly understood, both hematogenous and transneuronal pathways have been proposed^{50,51}. It has also been suggested that WNV crosses the BBB in the hematogenous pathway. WNV PAMPs orchestrate endothelial responses to WNV via competing PRRs, including TLR3-mediated innate immune cytokine signals at the BBB. While proinflammatory cytokines such as TNF- α and IL-1 β increase the permeability of endothelial barriers, type I and type III IFNs promote and stabilize the BBB^{17,20}. Another proinflammatory cytokine, osteopontin (OPN), compromises BBB integrity by recruiting WNV-infected polymorphonuclear neutrophil (PMN) infiltration and facilitates WNV entry via a Trojan horse mechanism⁵². WNV most likely propagates within the CNS transsynaptically by both anterograde and retrograde axonal transport⁵³. WNV-induced CNS diseases are caused partially by bystander damage from the immune response to virus infection in CNS-resident cells and/or infiltrating leukocytes following systemic immune responses. The trafficking of Ly6C^{hi} monocytes into the brain was pathogenic, as blocking these cells using anti-very late antigen 4 integrin antibody at the time of observation of the first weight loss and leukocyte influx resulted in long-term survival in mice with lethal encephalitis⁵⁴. In an *ex vivo* spinal cord slice culture (SCSC) model, it was shown that CNS-resident cells had the capacity to initiate a robust innate immune response against WNV infection in the absence of infiltrating inflammatory cells and systemic immune responses⁵⁵. Furthermore, treatment with minocycline in WNV-infected SCSC induced the expression of genes associated with the anti-inflammatory activation of microglia while inhibiting the expression of genes associated with proinflammatory microglia activation, and this was protective for multiple CNS cell types⁵⁶.

Many WNV virulent strains in lineages I and II have been reported to be associated with neurological diseases. Koutango virus (WNVKOU) belongs to lineages outside lineages I and II and was shown to be more virulent in mice than WNVNY99, a known virulent lineage I virus. The enhanced virulence of WNVKOU was associated with its poor viral clearance and the induction of a poor neutralizing antibody response⁵⁷.

WNV-induced neurological sequelae and chronic kidney disease

Some WNV convalescent patients develop persistent neurological sequelae and/or chronic kidney disease^{4,5}. The underlying mechanisms are not clearly understood. Vasek *et al.* recently developed a novel mouse model of human WNV neuroinvasive disease by using a WNV isolate with a point mutation in the NS5 protein (WNV-NS5-E218A), which induces infection with similar survival rates and cognitive dysfunction compared to humans. They demonstrated microglial engulfment of hippocampal CA3 presynaptic terminals via complement during acute WNV infection and after recovery⁵⁸. Furthermore, in the same mouse model, Garble *et al.* subsequently found that mice that had recovered from West Nile neuroinvasive disease exhibited fewer neuroblasts and increased astrogenesis without recovery

of hippocampal neurogenesis. Preferential generation of IL-1 in astrocytes impaired the homeostasis of neuronal progenitor cells⁵⁹. These results not only suggest a potential mechanism underlying neurocognitive impairment in patients recovering from WNV neuroinvasive disease but also provide potential therapeutic targets.

Increasing evidence suggests that persistent WNV infection also contributes to long-term morbidity. WNV antigen, RNA, or virus particles have been detected in the brain and/or urine of WNV patients ranging from a few months to several years after the initial acute illness^{60,61}. Small animal models have been developed to study persistent WNV infection. We and others have shown that the inbred C57BL6 mice infected with either the wild-type WNV strain or an isolate cultured from the urine of a persistently infected hamster share some similarity and discrepancy in symptoms and tissue tropism compared to the clinical findings in some WNV convalescent patients with long-term morbidity, including chronic kidney diseases and long-term neurological sequelae^{62,63}. More recently, the collaborative cross, a population of recombinant inbred mouse strains with high levels of fixed genetic variation, were used to investigate WNV persistence in the brain. Results from this model suggest that the Treg response sufficiently restrains the immune response and leads to WNV persistence in the CNS⁶⁴.

Conclusions

Studies in human cell culture and animal models suggest that both innate and adaptive immune responses are important for protecting the host from WNV infection. PRR-mediated innate immune responses are critical for the control of WNV dissemination and viral clearance in the CNS, modulation of BBB integrity, and regulation of the effector functions of innate and adaptive immune cells. Adaptive immunity provides long-lasting protection against WNV. Newly developed animal models have provided important insights into the mechanism underlying neurocognitive impairment in patients recovering from WNV neuroinvasive disease and WNV persistence in the CNS.

Competing interests

The authors declare that they have no competing interests.

Grant information

This work was supported in part by National Institutes of Health grant R01AI099123 (T.W.) and R01AI127744 (T.W.).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Straková P, Šikutová S, Jedličková P, *et al.*: **The common coot as sentinel species for the presence of West Nile and Usutu flaviviruses in Central Europe.** *Res Vet Sci.* 2015; **102**: 159–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
- <https://www.cdc.gov/westnile/statsmaps/cumMapsData.html>
- F** Patel CB, Trikamji BV, Mathisen GE, *et al.*: **Southern California neuroinvasive West Nile virus case series.** *Neurol Sci.* 2018; **39**(2): 251–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
- Nolan MS, Podoll AS, Hause AM, *et al.*: **Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort.** *PLoS One.* 2012; **7**(7): e40374.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Samaan Z, McDermid Vaz S, Bawor M, *et al.*: **Neuropsychological Impact of West Nile Virus Infection: An Extensive Neuropsychiatric Assessment of 49 Cases in Canada.** *PLoS One.* 2016; **11**(6): e0158364.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- F** Daffis S, Samuel MA, Suthar MS, *et al.*: **Toll-like receptor 3 has a protective role against West Nile virus infection.** *J Virol.* 2008; **82**(21): 10349–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- F** Town T, Bai F, Wang T, *et al.*: **Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing.** *Immunity.* 2009; **30**(2): 242–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Errett JS, Suthar MS, McMillan A, *et al.*: **The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection.** *J Virol.* 2013; **87**(21): 11416–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Ramos HJ, Lanteri MC, Blahnik G, *et al.*: **IL-1 β signaling promotes CNS-intrinsic immune control of West Nile virus infection.** *PLoS Pathog.* 2012; **8**(11): e1003039.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Schoggins JW, MacDuff DA, Imanaka N, *et al.*: **Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity.** *Nature.* 2014; **505**(7485): 691–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Paul AM, Acharya D, Le L, *et al.*: **TLR8 Couples SOCS-1 and Restrains TLR7-Mediated Antiviral Immunity, Exacerbating West Nile Virus Infection in Mice.** *J Immunol.* 2016; **197**(11): 4425–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- F** Lindqvist R, Mundt F, Gilthorpe JD, *et al.*: **Fast type I interferon response protects astrocytes from flavivirus infection and virus-induced cytopathic effects.** *J Neuroinflammation.* 2016; **13**(1): 277.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Thackray LB, Shrestha B, Richner JM, *et al.*: **Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile virus infection.** *J Virol.* 2014; **88**(19): 11007–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Cho H, Shrestha B, Sen GC, *et al.*: **A role for Ifit2 in restricting West Nile virus infection in the brain.** *J Virol.* 2013; **87**(15): 8363–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Lucas TM, Richner JM, Diamond MS: **The Interferon-Stimulated Gene *Irfi27l2a* Restricts West Nile Virus Infection and Pathogenesis in a Cell-Type- and Region-Specific Manner.** *J Virol.* 2015; **90**(5): 2600–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Gorman MJ, Poddar S, Farzan M, *et al.*: **The Interferon-Stimulated Gene *Irfm3* Restricts West Nile Virus Infection and Pathogenesis.** *J Virol.* 2016; **90**(18): 8212–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- F** Daniels BP, Holman DW, Cruz-Orengo L, *et al.*: **Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals.** *mBio.* 2014; **5**(5): e01476–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- F** Daniels BP, Juijavarapu H, Durrant DM, *et al.*: **Regional astrocyte IFN signaling restricts pathogenesis during neurotropic viral infection.** *J Clin Invest.* 2017; **127**(3): 843–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**

19. **F** Miner JJ, Daniels BP, Shrestha B, *et al.*: **The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity.** *Nat Med.* 2015; 21(12): 1464–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
20. **F** Lazear HM, Daniels BP, Pinto AK, *et al.*: **Interferon- λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier.** *Sci Transl Med.* 2015; 7(284): 284ra59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
21. Lazear HM, Lancaster A, Wilkins C, *et al.*: **IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling.** *PLoS Pathog.* 2013; 9(1): e1003118.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. **F** You F, Wang P, Yang L, *et al.*: **ELF4 is critical for induction of type I interferon and the host antiviral response.** *Nat Immunol.* 2013; 14(12): 1237–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
23. **F** Wang L, Yang L, Fikrig E, *et al.*: **An essential role of PI3K in the control of West Nile virus infection.** *Sci Rep.* 2017; 7(1): 3724.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
24. **F** Smith JL, Jeng S, McWeeney SK, *et al.*: **A MicroRNA Screen Identifies the Wnt Signaling Pathway as a Regulator of the Interferon Response during Flavivirus Infection.** *J Virol.* 2017; 91(8): pii: e02388–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
25. Li J, Ding SC, Cho H, *et al.*: **A short hairpin RNA screen of interferon-stimulated genes identifies a novel negative regulator of the cellular antiviral response.** *mBio.* 2013; 4(3): e00385–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Wang P, Yang L, Cheng G, *et al.*: **UBXN1 interferes with RIG-I-like receptor-mediated antiviral immune response by targeting MAVS.** *Cell Rep.* 2013; 3(4): 1057–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Crook KR, Miller-Kittrell M, Morrison CR, *et al.*: **Modulation of innate immune signaling by the secreted form of the West Nile virus NS1 glycoprotein.** *Virology.* 2014; 458–459: 172–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Qian F, Goel G, Meng H, *et al.*: **Systems immunology reveals markers of susceptibility to West Nile virus infection.** *Clin Vaccine Immunol.* 2015; 22(1): 6–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. **F** Bardina SV, Michlmayr D, Hoffman KW, *et al.*: **Differential Roles of Chemokines CCL2 and CCL7 in Monocytosis and Leukocyte Migration during West Nile Virus Infection.** *J Immunol.* 2015; 195(9): 4306–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
30. Durrant DM, Daniels BP, Pasioka T, *et al.*: **CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system.** *J Neuroinflammation.* 2015; 12: 233.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Ma DY, Suthar MS, Kasahara S, *et al.*: **CD22 is required for protection against West Nile virus Infection.** *J Virol.* 2013; 87(6): 3361–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. **F** Daniels BP, Snyder AG, Olsen TM, *et al.*: **RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation.** *Cell.* 2017; 169(2): 301–313.e11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
33. **F** Bielefeldt-Ohmann H, Bosco-Lauth A, Hartwig AE, *et al.*: **Characterization of non-lethal West Nile Virus (WNV) infection in horses: Subclinical pathology and innate immune response.** *Microb Pathog.* 2017; 103: 71–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
34. Zhang J, Wang J, Pang L, *et al.*: **The co-stimulatory effects of MyD88-dependent Toll-like receptor signaling on activation of murine $\gamma\delta$ T cells.** *PLoS One.* 2014; 9(9): e108156.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Xie G, Luo H, Pang L, *et al.*: **Dysregulation of Toll-Like Receptor 7 Compromises Innate and Adaptive T Cell Responses and Host Resistance to an Attenuated West Nile Virus Infection in Old Mice.** *J Virol.* 2015; 90(3): 1333–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Suthar MS, Brassil MM, Blahnik G, *et al.*: **A systems biology approach reveals that tissue tropism to West Nile virus is regulated by antiviral genes and innate immune cellular processes.** *PLoS Pathog.* 2013; 9(2): e1003168.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. **F** Zhao J, Vijay R, Zhao J, *et al.*: **MAVS Expressed by Hematopoietic Cells Is Critical for Control of West Nile Virus Infection and Pathogenesis.** *J Virol.* 2016; 90(16): 7098–108.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. **F** Giordano D, Draves KE, Young LB, *et al.*: **Protection of mice deficient in mature B cells from West Nile virus infection by passive and active immunization.** *PLoS Pathog.* 2017; 13(11): e1006743.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
39. **F** Graham JB, Da Costa A, Lund JM: **Regulatory T cells shape the resident memory T cell response to virus infection in the tissues.** *J Immunol.* 2014; 192(2): 683–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
40. **F** Richner JM, Gmyrek GB, Govero J, *et al.*: **Age-Dependent Cell Trafficking Defects in Draining Lymph Nodes Impair Adaptive Immunity and Control of West Nile Virus Infection.** *PLoS Pathog.* 2015; 11(7): e1005027.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
41. Xia J, Winkelmann ER, Gorder SR, *et al.*: **TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate.** *J Virol.* 2013; 87(22): 12090–101.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Luo H, Winkelmann E, Xie G, *et al.*: **MAVS Is Essential for Primary CD4⁺ T Cell Immunity but Not for Recall T Cell Responses following an Attenuated West Nile Virus Infection.** *J Virol.* 2017; 91(6): pii: e02097–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Xie G, Welte T, Wang J, *et al.*: **A West Nile virus NS4B-P38G mutant strain induces adaptive immunity via TLR7-MyD88-dependent and independent signaling pathways.** *Vaccine.* 2013; 31(38): 4143–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. **F** Lazear HM, Pinto AK, Ramos HJ, *et al.*: **Pattern recognition receptor MDA5 modulates CD8⁺ T cell-dependent clearance of West Nile virus from the central nervous system.** *J Virol.* 2013; 87(21): 11401–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
45. **F** Durrant DM, Robinette ML, Klein RS: **IL-1R1 is required for dendritic cell-mediated T cell reactivation within the CNS during West Nile virus encephalitis.** *J Exp Med.* 2013; 210(3): 503–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
46. **F** Durrant DM, Daniels BP, Klein RS: **IL-1R1 signaling regulates CXCL12-mediated T cell localization and fate within the central nervous system during West Nile Virus encephalitis.** *J Immunol.* 2014; 193(8): 4095–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
47. **F** Acharya D, Wang P, Paul AM, *et al.*: **Interleukin-17A Promotes CD8⁺ T Cell Cytotoxicity To Facilitate West Nile Virus Clearance.** *J Virol.* 2017; 91(1): pii: e01529–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
48. **F** Da Costa A, Garza E, Graham JB, *et al.*: **Extrinsic MAVS signaling is critical for Treg maintenance of Foxp3 expression following acute flavivirus infection.** *Sci Rep.* 2017; 7: 40720.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
49. Johnston LJ, Halliday GM, King NJ: **Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus.** *J Invest Dermatol.* 2000; 114(3): 560–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Nagata N, Iwata-Yoshikawa N, Hayasaka D, *et al.*: **The pathogenesis of 3 neurotropic flaviviruses in a mouse model depends on the route of neuroinvasion after viremia.** *J Neuropathol Exp Neurol.* 2015; 74(3): 250–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Suen WW, Prow NA, Hall RA, *et al.*: **Mechanism of West Nile virus neuroinvasion: a critical appraisal.** *Viruses.* 2014; 6(7): 2796–825.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. **F** Paul AM, Acharya D, Duty L, *et al.*: **Osteopontin facilitates West Nile virus neuroinvasion via neutrophil “Trojan horse” transport.** *Sci Rep.* 2017; 7(1): 4722.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
53. **F** Maximova OA, Bernbaum JG, Pletnev AG: **West Nile Virus Spreads Transsynaptically within the Pathways of Motor Control: Anatomical and Ultrastructural Mapping of Neuronal Virus Infection in the Primate Central Nervous System.** *PLoS Negl Trop Dis.* 2016; 10(9): e0004980.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
54. **F** Getts DR, Terry RL, Getts MT, *et al.*: **Targeted blockade in lethal West Nile virus encephalitis indicates a crucial role for very late antigen (VLA)-4-dependent recruitment of nitric oxide-producing macrophages.** *J Neuroinflammation.* 2012; 9: 246.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. **F** Quick ED, Leser JS, Clarke P, *et al.*: **Activation of intrinsic immune responses and microglial phagocytosis in an ex vivo spinal cord slice culture model of West Nile virus infection.** *J Virol.* 2014; 88(22): 13005–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
56. **F** Quick ED, Seitz S, Clarke P, *et al.*: **Minocycline Has Anti-inflammatory Effects and Reduces Cytotoxicity in an Ex Vivo Spinal Cord Slice Culture Model of West Nile Virus Infection.** *J Virol.* 2017; 91(22): pii: e00569–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
57. Prow NA, Setho YX, Biron RM, *et al.*: **The West Nile virus-like flavivirus**

Koutango is highly virulent in mice due to delayed viral clearance and the induction of a poor neutralizing antibody response. *J Virol*. 2014; **88**(17): 9947–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

58. **F** Vasek MJ, Garber C, Dorsey D, *et al.*: **A complement-microglial axis drives synapse loss during virus-induced memory impairment.** *Nature*. 2016; **534**(7608): 538–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
59. **F** Garber C, Vasek MJ, Vollmer LL, *et al.*: **Astrocytes decrease adult neurogenesis during virus-induced memory dysfunction via IL-1.** *Nat Immunol*. 2018; **19**(2): 151–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
60. Penn RG, Guarner J, Sejvar JJ, *et al.*: **Persistent neuroinvasive West Nile virus infection in an immunocompromised patient.** *Clin Infect Dis*. 2006; **42**(5): 680–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. **F** Murray KO, Kolodziej S, Ronca SE, *et al.*: **Visualization of West Nile Virus in Urine Sediment using Electron Microscopy and Immunogold up to Nine Years Postinfection.** *Am J Trop Med Hyg*. 2017; **97**(6): 1913–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
62. Appler KK, Brown AN, Stewart BS, *et al.*: **Persistence of West Nile virus in the central nervous system and periphery of mice.** *PLoS One*. 2010; **5**(5): e10649.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Saxena V, Xie G, Li B, *et al.*: **A hamster-derived West Nile virus isolate induces persistent renal infection in mice.** *PLoS Negl Trop Dis*. 2013; **7**(6): e2275.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. **F** Graham JB, Swarts JL, Wilkins C, *et al.*: **A Mouse Model of Chronic West Nile Virus Disease.** *PLoS Pathog*. 2016; **12**(11): e1005996.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Helle Bielefeldt-Ohmann**

Australian Infectious Diseases Research Centre, The University of Queensland, Queensland, Australia

Competing Interests: No competing interests were disclosed.

2. **Aaron C Brault**

Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research